Search

Your search keyword '"Vittorio Maglione"' showing total 97 results

Search Constraints

Start Over You searched for: Author "Vittorio Maglione" Remove constraint Author: "Vittorio Maglione"
97 results on '"Vittorio Maglione"'

Search Results

1. Extra X, extra questions: Trisomy X syndrome and IgA deficiency – a case report

2. Genome-wide screening in pluripotent cells identifies Mtf1 as a suppressor of mutant huntingtin toxicity

3. An interplay between UCP2 and ROS protects cells from high-salt-induced injury through autophagy stimulation

4. Blood–Brain Barrier Integrity Is Perturbed in a Mecp2-Null Mouse Model of Rett Syndrome

5. Curcumin C3 complex®/Bioperine® has antineoplastic activity in mesothelioma: an in vitro and in vivo analysis

6. Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease

7. Stimulation of Sphingosine Kinase 1 (SPHK1) Is Beneficial in a Huntington’s Disease Pre-clinical Model

8. Brain Region and Cell Compartment Dependent Regulation of Electron Transport System Components in Huntington’s Disease Model Mice

9. Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders

10. De novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's Disease

11. Impaired levels of gangliosides in the Corpus Callosum of Huntington Disease animal models

13. Nitric oxide dysregulation in platelets from patients with advanced Huntington disease.

14. Tractography of the corpus callosum in Huntington's disease.

15. Common and Rare Variants in TMEM175 Gene Concur to the Pathogenesis of Parkinson’s Disease in Italian Patients

17. Treatment with THI, an inhibitor of sphingosine-1-phosphate lyase, modulates glycosphingolipid metabolism and results therapeutically effective in experimental models of Huntington’s disease

23. <scp> TUBB3 E410K </scp> syndrome: Case report and review of the clinical spectrum of <scp> TUBB3 </scp> mutations

24. Treatment with the Glycosphingolipid Modulator THI Rescues Myelin Integrity in the Striatum of R6/2 HD Mice

25. Acute manganese treatment restores defective autophagic cargo loading in Huntington’s disease cell lines

26. Brain Region and Cell Compartment Dependent Regulation of Electron Transport System Components in Huntington’s Disease Model Mice

27. Differential Expression of Sphingolipid Metabolizing Enzymes in Spontaneously Hypertensive Rats: A Possible Substrate for Susceptibility to Brain and Kidney Damage

28. Polysialic Acid Sustains the Hypoxia-Induced Migration and Undifferentiated State of Human Glioblastoma Cells

29. A Rationale for Hypoxic and Chemical Conditioning in Huntington’s Disease

30. Curcumin-Loaded Nanoparticles Based on Amphiphilic Hyaluronan-Conjugate Explored as Targeting Delivery System for Neurodegenerative Disorders

31. Mitochondrial Respiration Changes in R6/2 Huntington’s Disease Model Mice during Aging in a Brain Region Specific Manner

32. New Therapeutic Drugs from Bioactive Natural Molecules: The Role of Gut Microbiota Metabolism in Neurodegenerative Diseases

33. Treatment with K6PC-5, a selective stimulator of SPHK1, ameliorates intestinal homeostasis in an animal model of Huntington's disease

34. The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatum–microglia crosstalk preventing disease progression in a mouse model of Huntington’s disease

35. Inhibition of Ceramide Synthesis Reduces α-Synuclein Proteinopathy in a Cellular Model of Parkinson’s Disease

36. Mutant huntingtin interacts with the sterol regulatory element-binding proteins and impairs their nuclear import

37. Stimulation of sphingosine kinase 1 (SPHK1) is beneficial in a Huntington's disease pre-clinical model

38. Curcumin dietary supplementation ameliorates disease phenotype in an animal model of Huntington's disease

39. I17 Curcumin-supplemented diet preserves body weight and ameliorates intestinal functionality in R6/2 mice

40. A25 Metabolism of sialo-conjugates is defective in pre-clinical models of huntington’s disease

41. I15 Inhibition of S1P degradation is beneficial in the transgenic R6/2 mouse model of huntington disease

42. I16 Stimulation of SPHK1 with selective activator K6PC-5 is beneficial in the transgenic R6/2 mouse model of huntington disease

43. Author Correction: Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease

44. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model

45. Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease

46. The S1P Axis: New Exciting Route for Treating Huntington's Disease

47. Glycosphingolipid metabolic reprogramming drives neural differentiation

48. The Corticospinal Tract in Huntington's Disease

49. MRI measures of corpus callosum iron and myelin in early Huntington's disease

50. Motor phenotype is not associated with vascular dysfunction in symptomatic Huntington’s disease transgenic R6/2 (160 CAG) mice

Catalog

Books, media, physical & digital resources